Novartis Ag (NVSEF) Return on Capital Employed (2009 - 2010)
Novartis Ag's (NVSEF) quarterly Return on Capital Employed came in at 0.0% in Q1 2010, down 2977.0% year-on-year from 0.0% in Q1 2009, and up 2550778.05% quarter-over-quarter from 0.0% in Q4 2009.
Novartis Ag (NVSEF) Return on Capital Employed (2009 - 2010) Analysis & Trends
Novartis Ag has disclosed Return on Capital Employed across 2 years of filings, most recently posting 0.0% for Q1 2010.
- Return on Capital Employed for Q1 2010 came in at 0.0%, down 2977.0% year-over-year; the trailing twelve-month figure through Mar 2010 was 0.0% (down 2977.0% YoY), and the FY2025 annual result was 22.24%, up 216.0% from the prior year.
- Return on Capital Employed came in at 0.0% for Q1 2010 at Novartis Ag, up from 0.0% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 29.77% in Q1 2009 to a low of 0.0% in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 9.49% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -6.84% |
| 10 | Novartis Ag | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2010 | 0.00% |
| Dec 31, 2009 | 0.00% |
| Sep 30, 2009 | 7.16% |
| Jun 30, 2009 | 7.12% |
| Mar 31, 2009 | 29.77% |